ASO Author Reflections: If at First You Don’t Succeed, Try, Try Again: Iterative CRS/HIPEC for Recurrent Mucinous Appendix Cancer
- 11.01.2022
- ASO Author Reflections
Erschienen in:
- Verfasst von
- Felipe Lopez-Ramirez
- Mary Caitlin King
- Vadim Gushchin
- Armando Sardi
- Erschienen in
- Annals of Surgical Oncology | Ausgabe 6/2022
Auszug
Repeating advanced regional therapies such as cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) after recurrence of appendiceal mucinous peritoneal carcinomatosis is a common practice with an acceptable safety profile.1,2 However, most of the data behind this practice are based on limited studies with mixed populations, so the decision to repeat CRS/HIPEC is likely based on resectability and patient status.3 Currently, there is no consensus on the best salvage treatment. Some patients are managed with systemic therapy, but the lack of an acceptable response to this alternative has led some peritoneal malignancy groups to repeat CRS/HIPEC regardless of tumor biology.1‐4 Thus, evidence behind this practice is still evolving, and much about patient selection, the effect of tumor biology, safety, feasibility, and the fate of non-candidate patients remains unknown. …
Anzeige
- Titel
- ASO Author Reflections: If at First You Don’t Succeed, Try, Try Again: Iterative CRS/HIPEC for Recurrent Mucinous Appendix Cancer
- Verfasst von
-
Felipe Lopez-Ramirez, MD
Mary Caitlin King, BS
Vadim Gushchin, MD, FACS
Armando Sardi, MD, FACS
- Publikationsdatum
- 11.01.2022
- Verlag
- Springer International Publishing
- Erschienen in
-
Annals of Surgical Oncology / Ausgabe 6/2022
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681 - DOI
- https://doi.org/10.1245/s10434-021-11235-z
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
